Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 7Hodgkin Disease 6Lymphoma, Large B-Cell, Diffuse 5Triple Negative Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Rhabdomyosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia 3Burkitt Lymphoma 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neuroblastoma 2Multiple Myeloma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Sleep Initiation and Maintenance Disorders 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Pancreatic Neoplasms 1Pain 1

Interventions

ibrutinib 5ruxolitinib 3Sirolimus 3Mycophenolic Acid 3fludarabine 2asciminib 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1montelukast 1axatilimab 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Specimen Handling 1Saline Solution 1Rituximab 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Panobinostat 1Methotrexate 1Mesna 1Infliximab 1Imatinib Mesylate 1Everolimus 1Erythropoietin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × pegfilgrastim × 1 year × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡